DOD’s 3Q Profit Soars 170% to Reach ฿73Million! Sales Jumps 80%

DOD Biotech Public Company Limited (DOD) has reported its financial statement through the Stock Exchange of Thailand as follows:

Net profit and net profit margin
In 3Q18, DOD  posted a net profit of ฿72.74 million, a year-on-year growth of ฿45.67 million or 168.71% with a net profit margin of 46.22%, up from 34.87% in the previous corresponding period on the back of a considerable increase in sales and significant increase in gross profit margin, which substantially pushed up its net profit and net profit margin.

 

Revenues from sales
DOD recorded revenues from sales in 3Q18 of ฿157.19 million, a year-on-year growth of ฿79.90 million or 103.38% mainly attributable to consistent orders from present customer and new customer.

Cost of sales and gross profit
DOD’s cost of sales in 3Q18 amounted to ฿57.43 million, rising year-on-year by ฿25.81 million or 81.63%, which was in line with the sharp increase in revenues from sales in this period. Gross profit margin in 3Q18 was 63.46%, going up by 59.09% year-on-year. The growth in 3Q18 gross profit margin was mainly driven by the adoption of economies of scale and efficient control of production cost.